SHIRE PHARMACEUTICALS GROUP
Company Information
- Company Number
- 02883758
- Registered Address
- 1 Kingdom Street, London, United Kingdom, W2 6BD
- Status
- Dissolved
- Employee Count
- 64
- Turnover
- £231,573,000
- EBITDA
- -£127,925,000
Additional Details
- Company Type
- Private unlimited company
- Incorporated On
- 1 January 1994
- Nature of Business
- 70100 - Activities of head offices
- Industries
- Professional Services
- Region
- London
Time to Pay
Payment Timeline
Payment Features
Company Review
Trend Analysis
The average time taken for SHIRE PHARMACEUTICALS GROUP to pay invoices has fluctuated over the past three periods, with a slight increase in 2019 followed by a decrease in 2020. However, the percentage of invoices paid within 30 days has remained relatively consistent, while the percentage of invoices paid later than 60 days has increased slightly over the past three periods.
Volatility Analysis
The average time taken for SHIRE PHARMACEUTICALS GROUP to pay invoices has varied by an average of 5.7% over the past three periods. The percentage of invoices paid within 30 days has varied by an average of 4.3%, while the percentage of invoices paid later than 60 days has varied by an average of 1.3% over the past three periods.
Summary Analysis
Between Jan 2018 and Mar 2020, SHIRE PHARMACEUTICALS GROUP has seen a decrease in the average time taken to pay invoices. The company has also maintained a relatively consistent percentage of invoices paid within 30 days, with a high of 65% in the second half of 2018 and a low of 53% in the first half of 2020. However, there has been a slight increase in the percentage of invoices paid later than 60 days, with a high of 22% in the first quarter of 2020.
Performance Reports History
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Apr 2020 - 30 Sept 2020 | 28 Oct 2020 | 53 | 63% | 18% | 19% | 26% |
| 01 Jan 2020 - 31 Mar 2020 | 24 Apr 2020 | 55 | 53% | 25% | 22% | 32% |
| 01 Jul 2019 - 31 Dec 2019 | 25 Feb 2020 | 52 | 56% | 25% | 19% | 26% |
| 01 Jan 2019 - 30 Jun 2019 | 30 Jul 2019 | 44 | 62% | 22% | 16% | 34% |
| 01 Jul 2018 - 31 Dec 2018 | 28 Jan 2019 | 38 | 65% | 19% | 16% | 53% |
| 01 Jan 2018 - 30 Jun 2018 | 27 Jul 2018 | 43 | 59% | 25% | 16% | 51% |
Payment Time Trends
Payment Distribution Trends
Invoice Payment Practices
This information is as reported by the business, and responses are in their own words.
Payment Terms
Standard payment terms
Terms are applied from invoice receipt date
Were there any changes to the standard payment terms in the reporting period?
No
Any other information about payment terms
N/A
Maximum contractual payment period agreed
60
Dispute Resolution Process
Takeda Business Solutions (TBS), is responsible for maintaining supplier information, PO processing, invoice processing and payments. Please note the following important points about contacting us.We operate a ticketing system to ensure all queries are recorded and responded to within agreed timelines.All new queries will be assigned a Case Number and [ref: XXX]These numbers should be quoted on all replies to TBS. You’ll find it in the subject line of our auto-reply. Please use this case number if following up on your email or reply directly to our case email. Query handing email address : accountspayableEU@shire.com
Other Payment Information
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
✅
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Company Summary
SHIRE PHARMACEUTICALS GROUP is a leading global biopharmaceutical company that focuses on developing innovative treatments for rare diseases. The company was founded in 1986 and is headquartered in Dublin, Ireland.
The company's sustainability program, known as "Sustainability 2020", aims to reduce their environmental impact, improve patient access to their medicines, and promote ethical business practices. As part of this program, SHIRE has implemented various initiatives such as reducing greenhouse gas emissions, using sustainable packaging materials, and promoting diversity and inclusion in their workforce.
SHIRE offers a range of products and services in the areas of rare diseases, neuroscience, immunology, and internal medicine. Their portfolio includes treatments for rare genetic disorders, such as Hunter syndrome and Fabry disease, as well as medicines for attention deficit hyperactivity disorder (ADHD) and inflammatory bowel disease (IBD).
The key people at SHIRE include CEO Flemming Ornskov, who has been with the company since 2013, and Chairman Susan Kilsby, who joined in 2014. The company has a team of over 23,000 employees across the globe, dedicated to improving the lives of patients with rare diseases.
For further information about SHIRE PHARMACEUTICALS GROUP and their products and services, you can visit their website at www.shire.com. The registered office address is Block 2, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland.
